British journal of haematology
Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.
Maximilian Fleischmann, Ole Hansen, Diana Voigtländer, Julia Bechwar, Lenny-Joseph Schwietzer, Sanja Bahr, Ulf Schnetzke, Mike Fischer, Florian H Heidel, Tina M Schnöder, Jörg P Müller, Andreas Hochhaus, Sebastian Scholl
Published: 202610.1111/bjh.70344
Abstract
Venetoclax (VEN)-based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non-receptor type 11 (PTPN11) and FMS like…
Preview only. Read the full abstract at the source